Clinical trial / 2023
Rosuvastatin reduced LDL-C significantly more than placebo and six dietary supplements, none of which lowered LDL-C compared with placebo.
Adults with an increased 10-year risk of ASCVD were randomized to rosuvastatin 5 mg daily, placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast rice for 28 days. A total of 190 participants completed the trial. Rosuvastatin achieved a greater percent LDL-C reduction than all supplements and placebo (P < 0.001), with a -35.2% difference compared with placebo (95% CI: -41.3% to -29.1%; P < 0.001). None of the dietary supplements demonstrated a significant decrease in LDL-C compared with placebo, and adverse event rates were similar across groups.
- Study type
- Single-center, prospective, randomized, single-blind clinical trial
- Who was studied
- 190 adults with no ASCVD history, LDL-C 70-189 mg/dL, and increased 10-year ASCVD risk
- What was measured
- Percent change in LDL-C from baseline after 28 days
THE PAPER
Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.
Laffin LJ, Bruemmer D, Garcia M, Brennan DM, McErlean E, Jacoby DS, Michos ED, Ridker PM, Wang TY, Watson KE, Hutchinson HG, Nissen SE. J Am Coll Cardiol, 2023.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.